• Zealand Pharma flagged positive Phase III results for Boehringer Ingelheim’s obesity drug candidate survodutide in adults with obesity and type 2 diabetes.
• Findings were presented at the EASD annual meeting and published in The New England Journal of Medicine.
• The trial hit its main goals, showing meaningful weight loss versus placebo in a population that typically loses less weight.
• Results also showed better blood-sugar control, supporting a broader cardiometabolic benefit alongside weight reduction.
• Gastrointestinal side effects drove a higher treatment stop rate than placebo, mainly during dose escalation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zealand Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010330OMX_____CNEWS_EN_GNW1001275683_en) on October 01, 2026, and is solely responsible for the information contained therein.